These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21692827)

  • 1. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis.
    Ternant D; Mulleman D; Lauféron F; Vignault C; Ducourau E; Wendling D; Goupille P; Paintaud G
    Br J Clin Pharmacol; 2012 Jan; 73(1):55-65. PubMed ID: 21692827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study.
    Mulleman D; Lauféron F; Wendling D; Ternant D; Ducourau E; Paintaud G; Goupille P
    Arthritis Res Ther; 2011 Jun; 13(3):R82. PubMed ID: 21639907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis.
    Xu Z; Seitz K; Fasanmade A; Ford J; Williamson P; Xu W; Davis HM; Zhou H
    J Clin Pharmacol; 2008 Jun; 48(6):681-95. PubMed ID: 18401017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study.
    Park W; Yoo DH; Jaworski J; Brzezicki J; Gnylorybov A; Kadinov V; Sariego IG; Abud-Mendoza C; Escalante WJ; Kang SW; Andersone D; Blanco F; Hong SS; Lee SH; Braun J
    Arthritis Res Ther; 2016 Jan; 18():25. PubMed ID: 26795209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis.
    Ternant D; Ducourau E; Perdriger A; Corondan A; Le Goff B; Devauchelle-Pensec V; Solau-Gervais E; Watier H; Goupille P; Paintaud G; Mulleman D
    Br J Clin Pharmacol; 2014 Jul; 78(1):118-28. PubMed ID: 24354889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement.
    Rejón E; Giménez MD; Mayordomo L; Rodríguez S; González MP; Marenco JL
    Scand J Rheumatol; 2004; 33(5):323-6. PubMed ID: 15513681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis.
    Pérez-Guijo VC; Cravo AR; Castro Mdel C; Font P; Muñoz-Gomariz E; Collantes-Estevez E
    Joint Bone Spine; 2007 May; 74(3):254-8. PubMed ID: 17387031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.
    Maksymowych WP; Jhangri GS; Lambert RG; Mallon C; Buenviaje H; Pedrycz E; Luongo R; Russell AS
    J Rheumatol; 2002 May; 29(5):959-65. PubMed ID: 12022358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Golder W; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Reddig J; Sieper J
    Arthritis Rheum; 2003 Aug; 48(8):2224-33. PubMed ID: 12905476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with seronegative spondyloarthritis continuing sulphasalazine and methotrexate after a short course of infliximab therapy--experience from a tertiary care teaching hospital in South India.
    Sandhya P; Danda D; Mathew J; Gattani A
    Clin Rheumatol; 2011 Jul; 30(7):997-1001. PubMed ID: 21409397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study.
    Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Mezières M; Alexandre C; Dougados M
    Rheumatology (Oxford); 2002 Nov; 41(11):1280-5. PubMed ID: 12422001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S; Brouwer E; van der Veer E; Groen H; Leijsma MK; Houtman PM; Th A Jansen TL; Kallenberg CG; Spoorenberg A
    Arthritis Res Ther; 2011 Jun; 13(3):R94. PubMed ID: 21689401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study.
    Saougou I; Markatseli TE; Voulgari PV; Drosos AA
    Joint Bone Spine; 2010 Jul; 77(4):325-9. PubMed ID: 20452801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab, a TNF-α antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level.
    Ertenli I; Ozer S; Kiraz S; Apras SB; Akdogan A; Karadag O; Calguneri M; Kalyoncu U
    Rheumatol Int; 2012 Feb; 32(2):323-30. PubMed ID: 21079965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial dysfunction in ankylosing spondylitis improves after tumor necrosis factor-alpha blockade.
    Syngle A; Vohra K; Sharma A; Kaur L
    Clin Rheumatol; 2010 Jul; 29(7):763-70. PubMed ID: 20204669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of the Bath Ankylosing Spondylitis Indices of disease activity (BASDAI), functional status (BASFI) and overall well-being (BAS-G) in anti-tumour necrosis factor-treated spondyloarthropathy patients.
    Madsen OR; Rytter A; Hansen LB; Suetta C; Egsmose C
    Clin Rheumatol; 2010 Aug; 29(8):849-54. PubMed ID: 20306214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.